Volume 16, issue 1, December 2016

948 articles in this issue

  1. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

    Authors (first, second and last of 22)

    • Christoph Rochlitz
    • Martin Bigler
    • on behalf of the Swiss Group for Clinical Cancer Research (SAKK)
    • Content type: Research article
    • Open Access
    • Published: 10 October 2016
    • Article: 780
    This is part of 1 collection: